|
WO2013066438A2
(en)
|
2011-07-22 |
2013-05-10 |
President And Fellows Of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
|
US20150044192A1
(en)
|
2013-08-09 |
2015-02-12 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a cas9 nuclease
|
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
|
US9340799B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
MRNA-sensing switchable gRNAs
|
|
US9737604B2
(en)
|
2013-09-06 |
2017-08-22 |
President And Fellows Of Harvard College |
Use of cationic lipids to deliver CAS9
|
|
US9388430B2
(en)
|
2013-09-06 |
2016-07-12 |
President And Fellows Of Harvard College |
Cas9-recombinase fusion proteins and uses thereof
|
|
US11053481B2
(en)
|
2013-12-12 |
2021-07-06 |
President And Fellows Of Harvard College |
Fusions of Cas9 domains and nucleic acid-editing domains
|
|
AU2015298571B2
(en)
|
2014-07-30 |
2020-09-03 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
|
US11279928B2
(en)
|
2015-06-29 |
2022-03-22 |
Massachusetts Institute Of Technology |
Compositions comprising nucleic acids and methods of using the same
|
|
US12043852B2
(en)
|
2015-10-23 |
2024-07-23 |
President And Fellows Of Harvard College |
Evolved Cas9 proteins for gene editing
|
|
US11845933B2
(en)
|
2016-02-03 |
2023-12-19 |
Massachusetts Institute Of Technology |
Structure-guided chemical modification of guide RNA and its applications
|
|
US10767175B2
(en)
|
2016-06-08 |
2020-09-08 |
Agilent Technologies, Inc. |
High specificity genome editing using chemically modified guide RNAs
|
|
KR20250103795A
(ko)
|
2016-08-03 |
2025-07-07 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
아데노신 핵염기 편집제 및 그의 용도
|
|
CN109804066A
(zh)
|
2016-08-09 |
2019-05-24 |
哈佛大学的校长及成员们 |
可编程cas9-重组酶融合蛋白及其用途
|
|
US11542509B2
(en)
|
2016-08-24 |
2023-01-03 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
|
AU2017342543B2
(en)
|
2016-10-14 |
2024-06-27 |
President And Fellows Of Harvard College |
AAV delivery of nucleobase editors
|
|
KR102551664B1
(ko)
*
|
2016-12-22 |
2023-07-05 |
인텔리아 테라퓨틱스, 인크. |
알파-1 항트립신 결핍을 치료하기 위한 조성물 및 방법
|
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
|
KR102712656B1
(ko)
|
2017-01-23 |
2024-10-04 |
리제너론 파마슈티칼스 인코포레이티드 |
Hsd17b13 변종 및 이것의 용도
|
|
EP3592853A1
(en)
|
2017-03-09 |
2020-01-15 |
President and Fellows of Harvard College |
Suppression of pain by gene editing
|
|
EP3592381A1
(en)
|
2017-03-09 |
2020-01-15 |
President and Fellows of Harvard College |
Cancer vaccine
|
|
KR20190127797A
(ko)
|
2017-03-10 |
2019-11-13 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
시토신에서 구아닌으로의 염기 편집제
|
|
CA3057192A1
(en)
|
2017-03-23 |
2018-09-27 |
President And Fellows Of Harvard College |
Nucleobase editors comprising nucleic acid programmable dna binding proteins
|
|
US11479802B2
(en)
|
2017-04-11 |
2022-10-25 |
Regeneron Pharmaceuticals, Inc. |
Assays for screening activity of modulators of members of the hydroxy steroid (17-beta) dehydrogenase (HSD17B) family
|
|
WO2018209320A1
(en)
|
2017-05-12 |
2018-11-15 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
|
|
EP3652312A1
(en)
|
2017-07-14 |
2020-05-20 |
Editas Medicine, Inc. |
Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
|
|
CN111801345A
(zh)
|
2017-07-28 |
2020-10-20 |
哈佛大学的校长及成员们 |
使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
|
|
KR102780441B1
(ko)
|
2017-07-31 |
2025-03-17 |
리제너론 파마슈티칼스 인코포레이티드 |
Cas-형질전환 마우스 배아 줄기 세포 및 마우스 및 이것의 용도
|
|
KR20200033259A
(ko)
|
2017-07-31 |
2020-03-27 |
리제너론 파마슈티칼스 인코포레이티드 |
생체내에서 CRISPR/Cas-매개된 파괴 또는 삭제 및 외인성 도너 핵산과의 CRISPR/Cas-유도된 재조합을 평가하기 위한 방법 및 조성물
|
|
WO2019139645A2
(en)
|
2017-08-30 |
2019-07-18 |
President And Fellows Of Harvard College |
High efficiency base editors comprising gam
|
|
WO2019067872A1
(en)
|
2017-09-29 |
2019-04-04 |
Intellia Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR EDITING THE TTR GENE AND TREATING AMYLOID DOSE ATTR
|
|
EP3585162B1
(en)
|
2017-09-29 |
2023-08-30 |
Regeneron Pharmaceuticals, Inc. |
Rodents comprising a humanized ttr locus and methods of use
|
|
AU2018348195B2
(en)
|
2017-10-11 |
2025-05-15 |
Regeneron Pharmaceuticals, Inc. |
Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation
|
|
CA3082251A1
(en)
|
2017-10-16 |
2019-04-25 |
The Broad Institute, Inc. |
Uses of adenosine base editors
|
|
EP3724214A4
(en)
|
2017-12-15 |
2021-09-01 |
The Broad Institute Inc. |
SYSTEMS AND METHODS FOR PREDICTING REPAIR RESULTS IN GENETIC ENGINEERING
|
|
US20190233816A1
(en)
*
|
2018-01-26 |
2019-08-01 |
Massachusetts Institute Of Technology |
Structure-guided chemical modification of guide rna and its applications
|
|
CN111885915B
(zh)
|
2018-03-19 |
2023-04-28 |
瑞泽恩制药公司 |
使用crispr/cas系统对动物进行转录调制
|
|
BR112020018758A2
(pt)
|
2018-03-21 |
2021-01-26 |
Regeneron Pharmaceuticals, Inc. |
agente de ácido ribonucleico de fita dupla, célula, vetor, composição farmacêutica, e, métodos para inibição da expressão de 17¿-hidroxiesteroide desidrogenases tipo 13, para tratamento de um indivíduo, para prevenção de um sintoma em um indivíduo, para redução do risco de desenvolver doença hepática crônica, para inibição da progressão de esteatose, para inibição do acúmulo de gotículas de lipídios
|
|
US12133884B2
(en)
|
2018-05-11 |
2024-11-05 |
Beam Therapeutics Inc. |
Methods of substituting pathogenic amino acids using programmable base editor systems
|
|
WO2019226953A1
(en)
|
2018-05-23 |
2019-11-28 |
The Broad Institute, Inc. |
Base editors and uses thereof
|
|
CA3104856A1
(en)
|
2018-06-29 |
2020-01-02 |
Editas Medicine, Inc. |
Synthetic guide molecules, compositions and methods relating thereto
|
|
CA3113190A1
(en)
|
2018-07-31 |
2020-02-06 |
Intellia Therapeutics, Inc. |
Compositions and methods for hydroxyacid oxidase 1 (hao1) gene editing for treating primary hyperoxaluria type 1 (ph1)
|
|
WO2020051283A1
(en)
|
2018-09-05 |
2020-03-12 |
The Regents Of The University Of California |
Generation of heritably gene-edited plants without tissue culture
|
|
WO2020051562A2
(en)
|
2018-09-07 |
2020-03-12 |
Beam Therapeutics Inc. |
Compositions and methods for improving base editing
|
|
BR112021005718A2
(pt)
|
2018-09-28 |
2021-06-22 |
Intellia Therapeutics, Inc. |
composições e métodos para edição de genes de lactato desidrogenase (ldha)
|
|
AU2019362879A1
(en)
|
2018-10-16 |
2021-05-27 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunotherapy
|
|
BR112021007301A2
(pt)
|
2018-10-18 |
2021-07-27 |
Intellia Therapeutics, Inc. |
composições e métodos para expressar fator ix
|
|
CN113195721A
(zh)
|
2018-10-18 |
2021-07-30 |
英特利亚治疗股份有限公司 |
治疗α-1抗胰蛋白酶缺乏症的组合物和方法
|
|
EP3867381A2
(en)
|
2018-10-18 |
2021-08-25 |
Intellia Therapeutics, Inc. |
Compositions and methods for transgene expression from an albumin locus
|
|
US12281338B2
(en)
|
2018-10-29 |
2025-04-22 |
The Broad Institute, Inc. |
Nucleobase editors comprising GeoCas9 and uses thereof
|
|
US12351837B2
(en)
|
2019-01-23 |
2025-07-08 |
The Broad Institute, Inc. |
Supernegatively charged proteins and uses thereof
|
|
DE112020001306T5
(de)
|
2019-03-19 |
2022-01-27 |
Massachusetts Institute Of Technology |
Verfahren und zusammensetzungen zur editierung von nukleotidsequenzen
|
|
CN118064502A
(zh)
|
2019-04-03 |
2024-05-24 |
瑞泽恩制药公司 |
用于将抗体编码序列插入到安全港基因座中的方法和组合物
|
|
ES2923629T3
(es)
|
2019-04-04 |
2022-09-29 |
Regeneron Pharma |
Métodos para la introducción sin cicatrices de modificaciones dirigidas en vectores de direccionamiento
|
|
AU2020253532B2
(en)
|
2019-04-04 |
2024-06-20 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized coagulation factor 12 locus
|
|
CN113966401A
(zh)
|
2019-04-10 |
2022-01-21 |
犹他大学研究基金会 |
用于治疗amd的htra1调节
|
|
US12473543B2
(en)
|
2019-04-17 |
2025-11-18 |
The Broad Institute, Inc. |
Adenine base editors with reduced off-target effects
|
|
US12365921B2
(en)
|
2019-05-30 |
2025-07-22 |
National University Corporation Hokkaido University |
Lipid nanoparticle
|
|
WO2020247452A1
(en)
|
2019-06-04 |
2020-12-10 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use
|
|
SG11202111256XA
(en)
|
2019-06-07 |
2021-11-29 |
Regeneron Pharma |
Non-human animals comprising a humanized albumin locus
|
|
CN114258398A
(zh)
|
2019-06-13 |
2022-03-29 |
总医院公司 |
工程化的人内源性病毒样颗粒及使用其递送至细胞的方法
|
|
WO2021050940A1
(en)
|
2019-09-13 |
2021-03-18 |
Regeneron Pharmaceuticals, Inc. |
Transcription modulation in animals using crispr/cas systems delivered by lipid nanoparticles
|
|
US12435330B2
(en)
|
2019-10-10 |
2025-10-07 |
The Broad Institute, Inc. |
Methods and compositions for prime editing RNA
|
|
EP4054651A1
(en)
|
2019-11-08 |
2022-09-14 |
Regeneron Pharmaceuticals, Inc. |
Crispr and aav strategies for x-linked juvenile retinoschisis therapy
|
|
WO2021108363A1
(en)
|
2019-11-25 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-mediated upregulation of humanized ttr allele
|
|
CN115176001A
(zh)
*
|
2019-12-11 |
2022-10-11 |
因特利亚治疗公司 |
用于基因编辑的修饰的引导rna
|
|
CN115362256A
(zh)
|
2020-02-07 |
2022-11-18 |
因特利亚治疗公司 |
用于激肽释放酶（klkb1）基因编辑的组合物和方法
|
|
AU2021230546A1
(en)
|
2020-03-04 |
2022-10-13 |
Flagship Pioneering Innovations Vi, Llc |
Methods and compositions for modulating a genome
|
|
EP4125348A1
(en)
|
2020-03-23 |
2023-02-08 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
|
|
BR112022020407A2
(pt)
*
|
2020-04-09 |
2023-05-02 |
Verve Therapeutics Inc |
Edição base do pcsk9 e métodos de uso do mesmo para tratamento de doenças
|
|
JP2023525304A
(ja)
|
2020-05-08 |
2023-06-15 |
ザ ブロード インスティテュート，インコーポレーテッド |
標的二本鎖ヌクレオチド配列の両鎖同時編集のための方法および組成物
|
|
CA3177463A1
(en)
*
|
2020-05-12 |
2021-11-18 |
Erik Joseph SONTHEIMER |
Modified guide rnas for crispr genome editing
|
|
BR112023001272A2
(pt)
|
2020-07-24 |
2023-04-04 |
Massachusetts Gen Hospital |
Partículas semelhantes a vírus aprimoradas e métodos de uso das mesmas para entrega às células
|
|
CN112111507B
(zh)
*
|
2020-08-10 |
2022-08-23 |
江苏大学 |
一种灰树花CRISPR-Cas9基因编辑系统、方法及应用
|
|
KR102493512B1
(ko)
*
|
2020-10-08 |
2023-02-01 |
주식회사 진코어 |
CRISPR/Cas12a 시스템을 위한 엔지니어링 된 crRNA
|
|
WO2022081702A1
(en)
*
|
2020-10-13 |
2022-04-21 |
The Trustees Of The University Of Pennsylvania |
In vivo targeting of cd4+-t cells for mrna therapeutics
|
|
US20220218622A1
(en)
|
2020-10-14 |
2022-07-14 |
George Mason Research Foundation, Inc. |
Ionizable lipids and methods of manufacture and use thereof
|
|
AU2021396403A1
(en)
|
2020-12-11 |
2023-06-29 |
Intellia Therapeutics, Inc. |
Compositions and methods for reducing mhc class ii in a cell
|
|
KR20230129996A
(ko)
|
2020-12-11 |
2023-09-11 |
인텔리아 테라퓨틱스, 인크. |
탈아미노화를 포함하는 게놈 편집을 위한 폴리뉴클레오타이드,조성물 및 방법
|
|
KR20230135068A
(ko)
|
2020-12-23 |
2023-09-22 |
인텔리아 테라퓨틱스, 인크. |
세포에서 ciita를 유전적으로 변형시키기 위한 조성물및 방법
|
|
AU2021409732A1
(en)
|
2020-12-23 |
2023-07-20 |
Intellia Therapeutics, Inc. |
Compositions and methods for reducing hla-a in a cell
|
|
MX2023007801A
(es)
|
2020-12-30 |
2023-08-21 |
Intellia Therapeutics Inc |
Células t diseñadas.
|
|
WO2022170059A1
(en)
|
2021-02-05 |
2022-08-11 |
Christiana Care Health Services, Inc. |
Methods of and compositions for reducing gene expression and/or activity
|
|
EP4288088A2
(en)
|
2021-02-08 |
2023-12-13 |
Intellia Therapeutics, Inc. |
Lymphocyte activation gene 3 (lag3) compositions and methods for immunotherapy
|
|
JP2024505672A
(ja)
|
2021-02-08 |
2024-02-07 |
インテリア セラピューティクス，インコーポレイテッド |
免疫療法のためのナチュラルキラー細胞受容体２ｂ４組成物及び方法
|
|
WO2022170193A2
(en)
|
2021-02-08 |
2022-08-11 |
Intellia Therapeutics, Inc. |
T-cell immunoglobulin and mucin domain 3 (tim3) compositions and methods for immunotherapy
|
|
KR102689529B1
(ko)
*
|
2021-06-28 |
2024-07-29 |
서울대학교산학협력단 |
sgRNA와 dCas9 간의 결합을 조절하여 박테리아에서 유전자 발현을 정량적으로 조절할 수 있는 방법
|
|
JP2024534114A
(ja)
|
2021-08-24 |
2024-09-18 |
インテリア セラピューティクス，インコーポレイテッド |
細胞療法用のプログラム細胞死タンパク質１（ｐｄ１）組成物及び方法
|
|
CA3231677A1
(en)
|
2021-09-08 |
2023-03-16 |
Flagship Pioneering Innovations Vi, Llc |
Methods and compositions for modulating a genome
|
|
AU2022345881A1
(en)
|
2021-09-20 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
|
|
WO2023047338A1
(en)
*
|
2021-09-24 |
2023-03-30 |
Crispr Therapeutics Ag |
PRODRUG INCORPORATED sgRNA SYNTHESIS
|
|
CN118251491A
(zh)
|
2021-10-28 |
2024-06-25 |
瑞泽恩制药公司 |
用于敲除C5的CRISPR/Cas相关方法及组合物
|
|
EP4426836A1
(en)
*
|
2021-11-03 |
2024-09-11 |
Intellia Therapeutics, Inc. |
Modified guide rnas for gene editing
|
|
CN118369110A
(zh)
|
2021-11-03 |
2024-07-19 |
英特利亚治疗股份有限公司 |
用于免疫疗法的cd38组合物和方法
|
|
CA3238939A1
(en)
|
2021-12-08 |
2023-06-15 |
Gaurang Patel |
Mutant myocilin disease model and uses thereof
|
|
TW202332767A
(zh)
|
2022-02-02 |
2023-08-16 |
美商雷傑納榮製藥公司 |
用於治療龐貝氏症之抗ＴｆＲ：ＧＡＡ及抗ＣＤ６３：ＧＡＡ插入
|
|
EP4514981A2
(en)
|
2022-04-29 |
2025-03-05 |
Regeneron Pharmaceuticals, Inc. |
Identification of tissue-specific extragenic safe harbors for gene therapy approaches
|
|
JP2025521154A
(ja)
|
2022-05-31 |
2025-07-08 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｃ９ｏｒｆ７２反復伸長疾患のためのｃｒｉｓｐｒ干渉療法
|
|
WO2023235725A2
(en)
|
2022-05-31 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Crispr-based therapeutics for c9orf72 repeat expansion disease
|
|
WO2023245113A1
(en)
|
2022-06-16 |
2023-12-21 |
Intellia Therapeutics, Inc. |
Methods and compositions for genetically modifying a cell
|
|
EP4547821A1
(en)
|
2022-06-29 |
2025-05-07 |
Intellia Therapeutics, Inc. |
Engineered t cells
|
|
JP2025528052A
(ja)
|
2022-07-29 |
2025-08-26 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
脳及び筋肉へのトランスフェリン受容体（ｔｆｒ）媒介送達のための組成物及び方法
|
|
CN120265314A
(zh)
|
2022-09-28 |
2025-07-04 |
瑞泽恩制药公司 |
抗体抗性修饰受体以增强基于细胞的疗法
|
|
CN120693347A
(zh)
|
2022-11-04 |
2025-09-23 |
瑞泽恩制药公司 |
钙电压门控通道辅助亚基γ1(CACNG1)结合蛋白和CACNG1介导的向骨骼肌的递送
|
|
EP4619438A2
(en)
|
2022-11-14 |
2025-09-24 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
|
|
WO2024137766A2
(en)
|
2022-12-21 |
2024-06-27 |
Intellia Therapeutics, Inc. |
Compositions and methods for proprotein convertase subtilisin kexin 9 (pcsk9) editing
|
|
TW202428878A
(zh)
|
2022-12-23 |
2024-07-16 |
美商英特利亞醫療公司 |
用於基因體編輯之系統及方法
|
|
WO2024186890A1
(en)
|
2023-03-06 |
2024-09-12 |
Intellia Therapeutics, Inc. |
Compositions and methods for hepatitis b virus (hbv) genome editing
|
|
TW202503051A
(zh)
|
2023-03-07 |
2025-01-16 |
美商英特利亞醫療公司 |
用於免疫療法之ｃｉｓｈ組合物及方法
|
|
CN121079412A
(zh)
*
|
2023-04-28 |
2025-12-05 |
比姆医疗股份有限公司 |
经修饰的指导rna
|
|
AU2024270764A1
(en)
|
2023-05-15 |
2025-12-04 |
Nchroma Bio, Inc. |
Compositions and methods for epigenetic regulation of hbv gene expression
|
|
WO2025006963A1
(en)
|
2023-06-30 |
2025-01-02 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for increasing homology-directed repair
|
|
WO2025006782A2
(en)
*
|
2023-06-30 |
2025-01-02 |
Chroma Medicine, Inc. |
Guide rna compositions
|
|
WO2025024486A2
(en)
|
2023-07-25 |
2025-01-30 |
Flagship Pioneering Innovations Vii, Llc |
Cas endonucleases and related methods
|
|
WO2025024493A1
(en)
|
2023-07-25 |
2025-01-30 |
Flagship Pioneering Innovations Vii, Llc |
Cas endonucleases and related methods
|
|
WO2025029654A2
(en)
|
2023-07-28 |
2025-02-06 |
Regeneron Pharmaceuticals, Inc. |
Use of bgh-sv40l tandem polya to enhance transgene expression during unidirectional gene insertion
|
|
WO2025029657A2
(en)
|
2023-07-28 |
2025-02-06 |
Regeneron Pharmaceuticals, Inc. |
Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe disease
|
|
US20250049896A1
(en)
|
2023-07-28 |
2025-02-13 |
Regeneron Pharmaceuticals, Inc. |
Anti-tfr:acid sphingomyelinase for treatment of acid sphingomyelinase deficiency
|
|
WO2025038637A1
(en)
|
2023-08-14 |
2025-02-20 |
Intellia Therapeutics, Inc. |
Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2)
|
|
WO2025038646A1
(en)
|
2023-08-14 |
2025-02-20 |
Intellia Therapeutics, Inc. |
Cd70 car-t compositions and methods for cell-based therapy
|
|
WO2025038648A1
(en)
|
2023-08-14 |
2025-02-20 |
Intellia Therapeutics, Inc. |
Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2)
|
|
WO2025038642A1
(en)
|
2023-08-14 |
2025-02-20 |
Intellia Therapeutics, Inc. |
Compositions and methods for genetically modifying cd70
|
|
WO2025049524A1
(en)
|
2023-08-28 |
2025-03-06 |
Regeneron Pharmaceuticals, Inc. |
Cxcr4 antibody-resistant modified receptors
|
|
WO2025072331A1
(en)
|
2023-09-26 |
2025-04-03 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
WO2025101994A2
(en)
|
2023-11-10 |
2025-05-15 |
Intellia Therapeutics, Inc. |
Compositions, methods, and systems for genomic editing
|
|
WO2025117877A2
(en)
|
2023-12-01 |
2025-06-05 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
WO2025128871A2
(en)
|
2023-12-13 |
2025-06-19 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2025137301A1
(en)
|
2023-12-20 |
2025-06-26 |
Intellia Therapeutics, Inc. |
Methods for rapid engineering of cells
|
|
WO2025137439A2
(en)
|
2023-12-20 |
2025-06-26 |
Intellia Therapeutics, Inc. |
Engineered t cells
|
|
WO2025184520A1
(en)
|
2024-02-29 |
2025-09-04 |
Intellia Therapeutics, Inc. |
Compositions and methods for angiopoietin like 3 (angptl3) editing
|
|
WO2025194138A1
(en)
|
2024-03-14 |
2025-09-18 |
Tessera Therapeutics, Inc. |
St1cas9 compositions and methods for modulating a genome
|
|
WO2025194124A1
(en)
*
|
2024-03-14 |
2025-09-18 |
Tessera Therapeutics, Inc. |
Modified st1cas9 guide nucleic acids
|
|
WO2025235388A1
(en)
|
2024-05-06 |
2025-11-13 |
Regeneron Pharmaceuticals, Inc. |
Transgene genomic identification by nuclease-mediated long read sequencing
|